Aytu Biopharma (AYTU) Receivables (2016 - 2025)
Historic Receivables for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $30.9 million.
- Aytu Biopharma's Receivables rose 2172.97% to $30.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $30.9 million, marking a year-over-year increase of 2172.97%. This contributed to the annual value of $31.2 million for FY2025, which is 3242.8% up from last year.
- Latest data reveals that Aytu Biopharma reported Receivables of $30.9 million as of Q4 2025, which was up 2172.97% from $33.2 million recorded in Q3 2025.
- Aytu Biopharma's Receivables' 5-year high stood at $35.8 million during Q1 2025, with a 5-year trough of $21.6 million in Q3 2021.
- For the 5-year period, Aytu Biopharma's Receivables averaged around $28.3 million, with its median value being $28.8 million (2021).
- As far as peak fluctuations go, Aytu Biopharma's Receivables skyrocketed by 43871.83% in 2021, and later tumbled by 2582.76% in 2024.
- Over the past 5 years, Aytu Biopharma's Receivables (Quarter) stood at $23.0 million in 2021, then increased by 11.13% to $25.5 million in 2022, then rose by 15.09% to $29.4 million in 2023, then fell by 13.6% to $25.4 million in 2024, then increased by 21.73% to $30.9 million in 2025.
- Its last three reported values are $30.9 million in Q4 2025, $33.2 million for Q3 2025, and $31.2 million during Q2 2025.